Inhibrx's Immunotherapy Combination Therapy Shows Promise

Inhibrx Biosciences (INBX), the developer of the investigational 6-epitope OX40 agonist INBRX-106, has announced interim results from a Phase 2 clinical trial evaluating INBRX-106 in combination with Merck's (MRK) Keytruda (pembrolizumab). The trial, conducted in patients with head and neck squamous cell carcinoma (HNSCC), demonstrated an objective response rate (ORR) of 44.0% for the combination therapy, more than double the 21.4% observed with Keytruda alone. Notably, three complete responses (CR) were observed in the combination arm, which were not seen in the single-agent arm, suggesting a synergistic effect. Inhibrx's market capitalization has recently increased to $2 billion, making it a prime M&A target for global pharmaceutical companies.

Argenx's Vyvgart Expands Market Reach

Argenx (ARGX) has received FDA approval to expand the label of its FcRn blocker, Vyvgart (efgartigimod alfa), to include all adult patients with generalized myasthenia gravis (gMG). This approval allows Vyvgart to be used in patients regardless of their antibody status, making it the only treatment option available for all gMG patients. This expansion is expected to increase Vyvgart's total addressable market (TAM) by approximately 18%. With sales of over $4 billion in 2025, Vyvgart is poised to further strengthen its market position.

Capricor and Nippon Shinyaku Dispute Over Deramiocel Contract

Capricor Therapeutics (CAPR) has filed a lawsuit against its partner, Nippon Shinyaku, seeking to terminate the U.S. distribution agreement for deramiocel, a therapy for Duchenne muscular dystrophy (DMD). The lawsuit alleges that the pricing mechanism outlined in the agreement will severely limit access to deramiocel for patients covered by public insurance programs. The agreement includes an upfront payment of $30 million and potential milestone payments of up to $705 million. This dispute raises concerns about the commercial launch of deramiocel, which is expected to receive FDA approval on August 22.

Fractyl Health's Gene Therapy for Diabetes Enters Clinical Trials

Fractyl Health (GUTS) has received approval from the Netherlands to initiate a Phase 1/2 clinical trial of RJVA-001, a single-dose, pancreatic-targeted gene therapy for diabetes. The therapy uses an AAV vector to deliver a gene that causes pancreatic beta cells to secrete GLP-1 in response to food. This novel mechanism of action has the potential to revolutionize the treatment of obesity and diabetes. The company plans to enroll the first patient in the trial in the second half of 2026 and expects to announce preliminary data shortly thereafter.

Partner Therapeutics Receives Additional Approval for Bizengri in Biliary Tract Cancer

Partner Therapeutics has received FDA approval to expand the label of Bizengri (zenocutuzumab-zbco) to include patients with NRG1-positive biliary tract cancer, leveraging the FDA's National Priority Voucher Program (CNPV). The therapy demonstrated an objective response rate (ORR) of 36.8% in clinical trials, providing a much-needed treatment option for patients with this rare and aggressive cancer. This approval also highlights the commercial value of the voucher program and its potential to accelerate the development of new therapies.